Semaglutide --- Research Product Overview

**Disclaimer:** This article is provided for educational and research purposes only. [Semaglutide](/research/semaglutide-metabolic) research material sold by Viking Labs is intended for laboratory research use only and is not intended for human consumption, diagnosis, or treatment of any condition. Nothing in this article constitutes medical advice. All references are to published peer-reviewed literature.

Overview

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Structurally, it is a 31-amino acid peptide based on the native human GLP-1(7-37) backbone with two amino acid substitutions (Aib at position 8, Arg at position 34) and a C18 fatty diacid chain attached via a gamma-Glu-2xOEG linker at Lys26. Together, these modifications confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage and produce strong, reversible binding to serum albumin --- the basis for semaglutide's extended in vivo half-life of approximately one week. Readers new to the incretin field should begin with our primer on the GLP-1 peptide revolution for context on the broader receptor class.

The peptide has a molecular formula of C187H291N45O59 and a molecular weight of approximately 4113.6 Da. It is an anionic peptide at physiological pH and is typically supplied as a lyophilized powder for reconstitution in sterile bacteriostatic water or sterile saline for laboratory use.

Sequence and Structural Notes

The full semaglutide sequence is:

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(gamma-Glu-2xOEG-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

The Aib (alpha-aminoisobutyric acid) substitution at position 8 protects against DPP-4-mediated cleavage at the His7-Ala8 bond, the principal degradation pathway for native GLP-1. The C18 diacid acylation at Lys26 binds reversibly to circulating albumin, slowing renal clearance and creating a depot effect at the injection site in vivo. These structural features are central to understanding the peptide's pharmacokinetic behavior in research models.

Mechanism of Action

Semaglutide is a selective agonist at the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, vagal afferents, gastric smooth muscle, and several CNS nuclei including the arcuate nucleus and area postrema. Binding to GLP-1R activates Gs-coupled adenylyl cyclase, increasing intracellular cAMP, activating PKA and Epac2, and ultimately enhancing glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells.

Outside the pancreas, GLP-1R activation in vagal and central nuclei modulates appetite signaling, gastric emptying rate, and reward-related circuitry. The peptide's slow off-rate and once-weekly pharmacokinetics produce sustained receptor engagement, distinguishing it pharmacologically from short-acting native GLP-1 or exenatide.

Comparator Peptides --- Semaglutide vs. Tirzepatide vs. Retatrutide

Semaglutide is the longest-studied of the modern long-acting incretin research peptides, and its pharmacology is most informative when contrasted with its dual- and triple-agonist successors. Our retatrutide vs. semaglutide vs. tirzepatide comparison covers these contrasts in greater depth, but a brief side-by-side is useful here.

Receptor selectivity. Semaglutide is a mono-agonist with subnanomolar potency at GLP-1R and minimal activity at GIPR or GCGR. Tirzepatide (LY3298176) is a balanced GLP-1R/GIPR dual agonist whose Aib-rich backbone produces a unique signaling profile, including biased agonism at GLP-1R that may reduce beta-arrestin recruitment relative to native GLP-1. Retatrutide (LY3437943) extends this concept to a triple-agonist (GLP-1R/GIPR/GCGR) and adds glucagon-receptor-driven energy expenditure to the incretin profile. See the tirzepatide dual agonist overview for details on its receptor pharmacology.

Half-life and pharmacokinetics. All three peptides use lipidation strategies to bind albumin and extend in vivo half-life beyond what is achievable with native incretin sequences. Semaglutide uses a C18 diacid; tirzepatide uses a C20 diacid; retatrutide uses a similar C20 fatty acid scaffold with a different linker geometry. Reported terminal half-lives in humans are roughly 165 hours for semaglutide, 120 hours for tirzepatide, and 160 hours for retatrutide, all supporting once-weekly dosing schedules.

Preclinical efficacy on body weight. In matched diet-induced obese (DIO) mouse studies, body-weight reduction generally tracks the receptor profile: semaglutide < tirzepatide < retatrutide. The differences are attributed primarily to additional receptor engagement (GIPR and then GCGR) rather than to GLP-1R potency itself. Our retatrutide triple agonist explainer breaks this hierarchy down with citations.

Deeper Preclinical Breakdown

Lau et al. (2015) --- Discovery and characterization. Published in J Med Chem, this paper reported the design rationale for semaglutide. The authors screened acyl-chain length, linker geometry, and backbone substitutions to identify a candidate with both DPP-4 resistance and high-affinity albumin binding. In vitro, semaglutide showed an EC50 of 0.1 nM at human GLP-1R (cAMP accumulation in BHK cells expressing recombinant receptor) and a half-life in db/db mice of approximately 46 hours. The paper's key methodological contribution was the systematic SAR around the Lys26 acylation, which established the "C18 diacid + gamma-Glu-2xOEG" linker as a generalizable strategy for once-weekly peptide therapeutics. Limitation: the paper used non-fasted glucose excursion as the primary efficacy readout, which underestimates effects on first-phase insulin secretion.

Gabery et al. (2020) --- Central GLP-1R engagement. This study mapped semaglutide's distribution in the rodent CNS using fluorescently labeled peptide and demonstrated direct uptake into circumventricular organs (area postrema, subfornical organ) plus indirect activation of arcuate nucleus POMC neurons via vagal afferents. Dosing protocol: 12 nmol/kg/day subcutaneously for 7-28 days in DIO mice. Key result: semaglutide reduced food intake by approximately 35% within 72 hours of treatment initiation, with effects persisting through chronic dosing. Limitation: the authors did not directly compare central vs. peripheral GLP-1R contributions using receptor-knockout models.

STEP 1 trial (Wilding et al., 2021). The first large-scale clinical demonstration of semaglutide 2.4 mg weekly in non-diabetic adults with overweight or obesity. While outside preclinical scope, STEP 1 anchors the translation of preclinical findings: the trial's mean -14.9% body-weight reduction at 68 weeks closely matches the dose-response curve predicted from DIO mouse studies, validating those models as predictive of human efficacy. Limitation: the trial population had limited cardiovascular comorbidity; SUSTAIN-6 and SELECT cover that gap.

Common Research Applications

In laboratory settings, semaglutide is commonly used as a reference GLP-1R agonist in:

• Receptor binding and functional assays (cAMP accumulation, beta-arrestin recruitment) in HEK293 or CHO cells expressing recombinant GLP-1R
• Rodent models of obesity, type 2 diabetes, and metabolic syndrome (DIO mice, ZDF rats, db/db mice)
• Comparative pharmacology against other incretin-class research peptides (e.g., tirzepatide, retatrutide)
• Hepatic steatosis and inflammation models (CDAA-HFD, MCD, GAN diet)
• Investigation of GLP-1R signaling bias and pathway-selective downstream activation

For deeper background on the peptide's clinical positioning, see what is semaglutide --- research guide.

Formulation Considerations

Lyophilized semaglutide is typically supplied as a fluffy white cake produced from acetate-buffered solution at pH 7.4. Reconstitution diluent of choice for laboratory work is sterile bacteriostatic water (0.9% benzyl alcohol) at 1-5 mg/mL; for cell-culture or in vivo work where benzyl alcohol is undesirable, sterile saline or PBS at pH 7.0-7.4 is acceptable but yields shorter solution stability.

The C18 diacid moiety makes semaglutide moderately surface-active; gentle inversion is preferred over vortexing during reconstitution to minimize foaming. Reconstituted semaglutide stored at 2-8 degrees C in glass vials retains greater than 95% main-peak HPLC purity for 28-56 days under aseptic conditions; plastic tubes (especially polypropylene) accelerate adsorption losses at low concentrations and warrant 0.1% BSA carrier in working stocks below 100 microgram/mL. Light exposure produces measurable photo-oxidation at the Trp25 indole over 7+ days at room temperature; amber vials or foil wrap mitigate this. Common impurities visible on the COA include the des-amidated Asn variant (peak typically 0.1-0.5%), oxidized Met (rare in semaglutide as Met is absent), and truncation products at the N-terminus from incomplete deprotection during synthesis. For broader formulation guidance, see our peptide reconstitution guide and peptide solubility guide.

Research-Context Dosing Ranges

In published preclinical literature, semaglutide doses in rodent models have ranged from approximately 1 to 60 nmol/kg administered subcutaneously, typically every 1-3 days. Lau et al. (2015) used 1.5 nmol/kg every other day in db/db mice; Gabery et al. (2020) used 12 nmol/kg/day in DIO mice; Kannt et al. (2021) used up to 60 nmol/kg in rat NAFLD models. In non-human primates (Gottingen minipigs and cynomolgus monkeys), 0.4-7 nmol/kg/week has been reported. These dosing ranges are provided strictly as references to the rodent and primate research literature and are not extrapolations to or recommendations for human use; semaglutide research material sold by Viking Labs is for laboratory research only.

Handling, Reconstitution, and Storage

Lyophilized semaglutide is generally stable at -20 degrees C for 24+ months when stored sealed and protected from light. Once reconstituted in sterile bacteriostatic water (typically at 1-5 mg/mL for laboratory work), the peptide should be stored at 2-8 degrees C and used within approximately 28-56 days, depending on buffer composition and aseptic technique. Avoid repeated freeze-thaw cycles, which can promote aggregation of the lipidated peptide. The C18 diacid moiety makes semaglutide modestly more hydrophobic than native GLP-1, so gentle swirling rather than vigorous shaking is recommended during reconstitution to minimize foaming and surface adsorption losses. See our broader peptide storage and stability reference for parallel guidance on related lipidated peptides.

HPLC Purity and Lab Specifications

Research-grade semaglutide should meet the following typical specifications:

• HPLC purity: greater than or equal to 98.0% by RP-HPLC (UV detection at 214 nm)
• Mass confirmation: ESI-MS or MALDI-TOF matching theoretical [M+H]+ within 1 Da
• Acetate or TFA counterion content reported on the COA
• Endotoxin: less than 5 EU/mg (for cell culture or in vivo research applications)
• Residual solvents: within ICH Q3C limits

For guidance on interpreting third-party certificates of analysis, see How to read a peptide COA and our companion piece on reading HPLC COA reports.

Cross-References --- Related Viking Labs Research

For deeper exploration of related topics on the Viking Labs research index:

• GLP-1 peptide revolution --- the receptor class context
• Tirzepatide dual agonist overview --- GIPR co-engagement
• Retatrutide 10 mg vial --- triple-agonist research peptide
• Retatrutide vs. semaglutide vs. tirzepatide --- direct comparator analysis
• Peptide reconstitution guide --- formulation reference
• Understanding peptide purity --- HPLC interpretation
• Research peptide buying guide --- vendor evaluation framework

*Provided for laboratory research purposes only. Not for human or veterinary use.*